Is HALO or DFTX the better stock?

HALO scores higher: HALO 78.7, DFTX 17.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.

Where do HALO and DFTX differ most?

The widest gap is growth, where HALO leads by 87 points on the 0–100 pillar scale. HALO leads all three pillars, so the gap is broad rather than a single-measure difference.

How are HALO and DFTX scored?

Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.

How current is this comparison?

The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.

COMPARE · Data as of August 27, 2026

DFTX vs HALO

Verdict: Side-by-side breakdown using the Bull Rankings model. DFTX scored 17.0, HALO scored 78.7 — HALO leads.

Compare another set

DFTX

Definium Therapeutics, Inc.

Biotechnology · Quality-Growth

$43.82 · $5.9B

fundamentals as of Jun 2026

Score gap

61.7

HALO leads

HALO

Halozyme Therapeutics, Inc.

Biotechnology · Quality-Growth

78.7

$108.63 · $12.3B

fundamentals as of Jun 2026

At a glance · who leads each dimension, on the model's own rules

Highest qualityHALO96 / 100
Largest discount to fair valueHALO-38%

Side by side · every name on one set of axes

The model, pillar by pillar (0–100 each)

DFTX

stronger →← stronger

HALO

Qualityreturns · margins · balance sheet

Growthrevenue & earnings expansion

Valuevaluation vs sector peers

HALO is stronger on 3 of 3 pillars.

Fundamentals, head-to-head

DFTX

HALO

-$168mF

FCF

$806mC+

—

Rev

+41.2%A

0.04A-

D/E

—

PEG

1.51C+

—

P/E

31.9xB

Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.

Valuation · DCF cross-check

DFTX

HALO

—

Price vs fair valuelower is cheaper

38% below

—

Growth the price implies10-yr FCF · lower = less priced in

~1%/yr

—

1-yr DCF upside

+29%

—

5-yr DCF upside

+62%

—

10-yr DCF upside

+128%

The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.

Model signals

DFTX

Why this score

Diluting shareholders

HALO

Why this score

Buying back stock
Durable high returns

The companies

DFTXDefinium Therapeutics, Inc.

Biotechnology · $43.82 · beta 2.26

Why now

Biotechnology · market cap $5.9b. 12% off the 52-week high of $49.70. 17 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $67.47 (implying +54% upside).

Moat

Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.

Risk

Free cash flow is negative (-$168m) — capital raises or debt issuance likely required; dilution / leverage risk. Beta 2.26 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -39% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.

HALOHalozyme Therapeutics, Inc.

Biotechnology · $108.63 · beta 0.85

Why now

Biotechnology · market cap $12.3b. Trading near 52-week high of $109.65 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).

Moat

Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.

Risk

Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.

Verdict — model-derived comparison

Generating verdict… typically 5–10 seconds

Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where DFTX and HALO diverge

On the headline score the gap is 61.7 points in favor of HALO. The widest single difference is Growth, where HALO leads by 87.0 points.

GrowthDFTX 10.0 · HALO 97.0HALO +87.0
QualityDFTX 21.0 · HALO 95.7HALO +74.7
ValueDFTX 23.2 · HALO 52.6HALO +29.4

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.